| human | Q5 |
| P7893 | CIÊNCIAVITAE ID | 571D-96F7-0457 |
| P6178 | Dimensions author ID | 01027003236.41 |
| P2798 | Loop ID | 44527 |
| P3835 | Mendeley person ID | paula-soares7 |
| P496 | ORCID iD | 0000-0001-9607-6998 |
| P3829 | Publons author ID | 1169761 |
| P1053 | ResearcherID | B-6054-2008 |
| P1153 | Scopus author ID | 57195213812 |
| P108 | employer | i3S - Health Research and Innovation Institute | Q107519189 |
| Institute of Molecular Pathology and Immunology of the University of Porto | Q6040646 | ||
| Faculty of Medicine of the University of Porto | Q10279533 | ||
| P734 | family name | Soares | Q20823845 |
| P735 | given name | Paula | Q847179 |
| Paula | Q847179 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q90359777 | "The other side of the coin": understanding noninvasive follicular tumor with papillary-like nuclear features in unifocal and multifocal settings |
| Q95931114 | A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms-Granting a Positive Outcome |
| Q57558985 | A Polymorphism in the Promoter Region of the Selenoprotein S Gene (SEPS1) Contributes to Hashimoto's Thyroiditis Susceptibility |
| Q42913067 | A clear cell renal cell carcinoma inhibiting the response to intravitreal antivascular endothelial growth factor therapy in wet age-related macular disease |
| Q54716120 | A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. |
| Q57687918 | A founder SDHB mutation in Portuguese paraganglioma patients |
| Q60526951 | A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney–Stratakis dyad |
| Q53357270 | A stem cell role for thyroid solid cell nests |
| Q40135421 | A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation |
| Q27851932 | AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines |
| Q60527150 | Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant |
| Q60526751 | Absence of theBRAFand theGRIM-19Mutations in Oncocytic (Hürthle Cell) Solid Cell Nests of the Thyroid |
| Q45098450 | Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma |
| Q60527124 | Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes |
| Q88146385 | Age-Associated Mortality Risk in Papillary Thyroid Cancer: Does BRAF Make a Real Difference? |
| Q59892699 | Alopecia in women submitted to childhood X-ray epilation for tinea capitis treatment |
| Q54518330 | An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis. |
| Q60527002 | Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas |
| Q60527142 | BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC |
| Q60527136 | BRAF mutations are associated with some histological types of papillary thyroid carcinoma |
| Q40031893 | BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations |
| Q60527090 | BRAFV600Emutation in papillary thyroid carcinoma: a potential target for therapy? |
| Q60527157 | Benign and malignant thyroid lesions show instability at microsatellite loci |
| Q92663356 | Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review |
| Q59600675 | C-Cell-Derived Calcitonin-Free Neuroendocrine Carcinoma of the Thyroid |
| Q60526957 | CDX2 Expression in Some Variants of Papillary Thyroid Carcinoma |
| Q49233052 | CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension |
| Q41722987 | Calcitonin receptor expression in medullary thyroid carcinoma |
| Q39634789 | Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells |
| Q100313497 | Clinical Validation of a Urine Test (Uromonitor-V2®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients |
| Q101158995 | Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma |
| Q59182889 | Clonal cytogenetic abnormalities and telomeric associations in a fibroxanthoma of the stomach |
| Q55068563 | Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis? |
| Q60527154 | Comments on: Mutations in Mitochondrial Control Region DNA in Gastric Tumours of Japanese Patients, Tamura, et al. Eur J Cancer 1999, 35, 316–319 |
| Q97568199 | Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours |
| Q24796416 | Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid |
| Q42426047 | Corrigendum to "How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer". |
| Q60527092 | Cribriform-Morular Variant of Papillary Thyroid Carcinoma |
| Q59600687 | Cribriform-Morular Variant of Papillary Thyroid Carcinoma Displaying Poorly Differentiated Features |
| Q60526742 | Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/β-catenin pathway |
| Q39938669 | Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation |
| Q81410806 | Cystic tumor of the atrioventricular node of the heart appears to be the heart equivalent of the solid cell nests (ultimobranchial rests) of the thyroid |
| Q54426394 | Cytogenetic findings in eleven gastric carcinomas |
| Q93178947 | Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors |
| Q35600108 | Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature. |
| Q43961750 | Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. |
| Q52692095 | Dynamin-Related Protein 1 at the Crossroads of Cancer. |
| Q59182686 | E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma |
| Q60527159 | E-cadherin gene alterations are rare events in thyroid tumors |
| Q53780532 | E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas |
| Q39633184 | EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide |
| Q26778154 | ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome |
| Q97522197 | Erratum to "Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism" |
| Q61050529 | Erratum: Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells |
| Q39421661 | Etiopathogenesis of oncocytomas |
| Q43154862 | Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma |
| Q57981783 | Extended structural variation of a pentanucleotide repeat in the GSTP1 gene: characterisation in a normal population and in thyroid and gastric tumours |
| Q60527151 | Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern |
| Q59600725 | Follicular thyroid carcinoma with an unusual glomeruloid pattern of growth |
| Q57301016 | Follicular thyroid lesions: is there a discriminatory potential in the computerized nuclear analysis? |
| Q73305796 | Four novel MSH2 / MLH1 gene mutations in portuguese HNPCC families |
| Q39120274 | Frequency of TERT promoter mutations in human cancers |
| Q42513234 | Frontiers in endocrine disruption: Impacts of organotin on the hypothalamus-pituitary-thyroid axis |
| Q39061082 | GLUT1, MCT1/4 and CD147 overexpression supports the metabolic reprogramming in papillary renal cell carcinoma |
| Q37058301 | GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. |
| Q37888005 | GRIM-19 function in cancer development |
| Q46834896 | GRIM-19 in Health and Disease. |
| Q95729496 | Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism |
| Q35731037 | Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas |
| Q47728142 | Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment |
| Q52598582 | Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background |
| Q44616534 | Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. |
| Q33822934 | Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer. |
| Q46987224 | H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid |
| Q42502843 | Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment |
| Q60527025 | Head and neck lesions in a cohort irradiated in childhood for tinea capitis treatment |
| Q52937126 | Hobnail Variant of Papillary Thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases. |
| Q41156947 | Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. |
| Q37902072 | How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer |
| Q36142967 | IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort |
| Q60527078 | Identification of a paired box gene 8–peroxisome proliferator-activated receptor gamma (PAX8–PPARγ) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH recept |
| Q44455244 | Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production. |
| Q48870888 | Impact of EGFR genetic variants on glioma risk and patient outcome. |
| Q42811031 | In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp |
| Q59600680 | Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease) |
| Q47765421 | Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer |
| Q38012466 | Insights into melanoma: targeting the mTOR pathway for therapeutics |
| Q37172760 | Intragenic mutations in thyroid cancer. |
| Q54550197 | Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. |
| Q59600637 | Introduction |
| Q34636091 | Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. |
| Q39936134 | Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer? |
| Q57558983 | Is Low-Dose Radiation Exposure a Risk Factor for Atherosclerotic Disease? |
| Q58923767 | Liposomal therapies in oncology: does one size fit all? |
| Q59182898 | Loss of Y chromosome in gastric carcinoma |
| Q58876485 | Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma |
| Q36695151 | Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). |
| Q54475618 | MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism |
| Q58886959 | Melanocytic Tumour in a Black Sheep never exposed to Ultraviolet Radiation |
| Q55217220 | Melanoma treatment in review. |
| Q60527152 | Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma |
| Q60527129 | Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy |
| Q42445888 | Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. |
| Q35231712 | Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration |
| Q35910367 | Molecular Alterations in Sporadic Primary Hyperparathyroidism |
| Q100759138 | Molecular Aspects of Thyroid Calcification |
| Q38754009 | Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes |
| Q36809668 | Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors. |
| Q40088475 | Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines |
| Q55033322 | Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. |
| Q52546126 | Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex |
| Q34105829 | Multicentre validation study of nucleic acids extraction from FFPE tissues. |
| Q52655919 | Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome: Histologic and Molecular Alterations. |
| Q55471458 | Mutation analysis of B-RAF gene in human gliomas. |
| Q47212889 | NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features |
| Q39139732 | Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells |
| Q57063932 | OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines |
| Q38928748 | OXPHOS dysfunction regulates integrin-β1 modifications and enhances cell motility and migration. |
| Q42686258 | Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal |
| Q57987153 | Optimization of methods to assess mitochondrial DNA in archival paraffin-embedded tissues from mammary canine tumors |
| Q39496999 | Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR. |
| Q38799394 | Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma |
| Q37588399 | Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior |
| Q59600641 | Other Rare Tumours and Tumour-Like Lesions |
| Q38874710 | Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. |
| Q38176686 | Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? |
| Q37985598 | Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review. |
| Q34051020 | Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease |
| Q26801388 | Poorly Differentiated and Undifferentiated Thyroid Carcinomas |
| Q98173831 | Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer |
| Q34247151 | Primary squamous cell carcinoma of the thyroid diagnosed as anaplastic carcinoma: failure in fine-needle aspiration cytology? |
| Q97522949 | Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas |
| Q38184374 | Prognostic biomarkers in thyroid cancer |
| Q33514138 | Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. |
| Q72678716 | Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies |
| Q38844306 | RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation |
| Q55065985 | RE: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. |
| Q38026893 | RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. |
| Q59600642 | Rare Familial Tumours |
| Q59600644 | Rare Follicular Tumours |
| Q59600645 | Rare Papillary Thyroid Carcinomas |
| Q57721392 | Relative Y-STR mutation rates estimated from the variance inside SNP defined lineages |
| Q90108115 | Reliable blood cancer cells' telomere length evaluation by qPCR |
| Q60527133 | Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas |
| Q33853615 | SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma |
| Q28505424 | STAT3 negatively regulates thyroid tumorigenesis |
| Q91120039 | Scalp basal cell carcinoma: A different entity? |
| Q57026318 | Selenium and Selenoproteins in Immune Mediated Thyroid Disorders |
| Q59182902 | Signet Ring Cell Carcinoma of the Stomach: A Morphometric, Ultrastructural, and DNA Cytometric Study |
| Q59600648 | Small Cell Tumours |
| Q60527006 | Small papillary thyroid cancers—is BRAF of prognostic value? |
| Q36615843 | Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. |
| Q50869606 | Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? |
| Q44740153 | Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later |
| Q39282539 | Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes |
| Q52726251 | Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death |
| Q89551068 | TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients |
| Q39037274 | TERT biology and function in cancer: beyond immortalisation |
| Q34313648 | TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
| Q91232481 | TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma |
| Q37093384 | TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes |
| Q42456732 | TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. |
| Q53337795 | TERT promoter mutations in soft tissue sarcomas |
| Q40497799 | TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation |
| Q51092203 | TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease |
| Q89287810 | TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma |
| Q46103524 | TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma |
| Q115193317 | Tackling Thyroid Cancer in Europe-The Challenges and Opportunities |
| Q28068238 | Telomerase Activation in Hematological Malignancies |
| Q51304058 | Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas |
| Q47878443 | Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q39403393 | The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications |
| Q28071562 | The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype |
| Q38003587 | The biology and the genetics of Hurthle cell tumors of the thyroid. |
| Q60526744 | The environmental contaminant tributyltin leads to abnormalities in different levels of the hypothalamus-pituitary-thyroid axis in female rats |
| Q90363488 | The genetics of cutaneous squamous cell carcinogenesis |
| Q24627306 | The mTOR Signalling Pathway in Human Cancer |
| Q60527119 | The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma |
| Q59600708 | The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases |
| Q60526771 | The role of ablative treatment in differentiated thyroid cancer management |
| Q59600651 | Therapeutic Options |
| Q59600655 | Thyroid and Parathyroid Glands |
| Q52801149 | Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950-1963). |
| Q37823747 | Thyroid hormone as a regulator of tumor induced angiogenesis |
| Q52310317 | Tributyltin and Zebrafish: Swimming in Dangerous Water. |
| Q44819624 | Tumor-in-tumor of the thyroid with basaloid differentiation: a lesion with a solid cell nest neoplastic component? |
| Q60527135 | Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness |
| Q90148627 | Unraveling molecular targets of bisphenol A and S in the thyroid gland |
| Q35055394 | Vascular invasion in thyroid and gastric carcinomas. |
| Q53682892 | mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. |
| Q55071575 | mTOR activation in medullary thyroid carcinoma with RAS mutation. |
| Q54637612 | mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. |
| Q39355399 | mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. |
| Q42435716 | p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin |
| Q40602311 | pmTOR is a marker of aggressiveness in papillary thyroid carcinomas |
Search more.